Dr. Reddy's Laboratories (NYSE:RDY) Reaches New 12-Month Low - What's Next?

Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $13.05 and last traded at $13.07, with a volume of 7384 shares. The stock had previously closed at $13.49.

Wall Street Analyst Weigh In

RDY has been the subject of a number of recent research reports. Barclays decreased their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a report on Wednesday, November 6th. StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Finally, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Price Performance

The business's fifty day simple moving average is $14.51 and its 200-day simple moving average is $15.10. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.66 billion, a P/E ratio of 20.33 and a beta of 0.50.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. increased its stake in Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Royal Bank of Canada increased its stake in Dr. Reddy's Laboratories by 403.1% in the fourth quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock valued at $158,489,000 after acquiring an additional 8,042,163 shares during the last quarter. Renaissance Technologies LLC increased its stake in Dr. Reddy's Laboratories by 382.9% in the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after acquiring an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd increased its stake in Dr. Reddy's Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after acquiring an additional 4,523,303 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Dr. Reddy's Laboratories by 405.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after acquiring an additional 4,301,212 shares during the last quarter. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.